- Organic revenue growth1 of 4% driven by
Care Enablement and Care Delivery
- Underlying U.S. same market treatment growth further
accelerated in Q4 and turned positive for the full year
- Accumulated savings of the FME25 program already
reached EUR 567 million and 2025 target raised to EUR 750 million
- With 18% operating income2 growth top end of the
2024 outlook range reached
- Reported operating income grew by 2%, reported net
income3 by +8%
- Net financial leverage ratio reduced from 3.2x to 2.9x and
dividend is planned to be raised by 21%
- High teens to high twenties percent earnings growth in 2025,
translating into an 11 to 12% margin
BAD HOMBURG, Germany, Feb. 25,
2025 /PRNewswire/ -- "Fresenius Medical Care has
again delivered against its commitments and we met the top end of
our 2024 target to profitably grow our business. We successfully
executed against our strategic turnaround and transformation plan,
advancing our legacy portfolio optimization and realizing
significant FME25 savings ahead of plan. The momentum we have
created enables us to further raise our FME25 savings target from
EUR 650 million to EUR 750 million", said Helen Giza, Chief Executive Officer of Fresenius
Medical Care AG. "Our continued focus on improving operational
performance resulted in meaningful progress in the operating income
margin towards our 2025 margin targets. Over the course of the past
financial year, both business segments contributed to the positive
development." Giza added: "In Care Delivery, a key milestone was
underlying U.S. same market treatment growth remaining positive for
the second consecutive quarter and turning positive for the full
year. Care Enablement recorded accelerated volume growth alongside
continued positive pricing momentum. The strong operating income
improvement of Care Enablement is testimony to delivering on our
ambitious transformation plan. We are confident in the continued
execution of our 2025 strategy. We have set the course to
significantly grow earnings, raising the implied operating income
margin to around 11 to 12 percent in 2025. I would like to thank
our employees for their unwavering commitment in providing high
quality of patient care worldwide, every day."
|
Key figures Q4 and
FY 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q4 2024
|
Q4 2023
|
Growth
|
Growth
|
FY 2024
|
FY 2023
|
Growth
|
Growth
|
|
EUR m
|
EUR m
|
yoy
|
yoy, cc
|
EUR m
|
EUR m
|
yoy
|
yoy, cc
|
|
Revenue
|
5,085
|
4,988
|
+2 %
|
+2 %
|
19,336
|
19,454
|
-1 %
|
0 %
|
|
on outlook
base2
|
5,069
|
4,834
|
|
+5 %
|
19,454
|
19,049
|
|
+2 %
|
|
|
|
|
|
|
|
|
|
|
Operating
income
|
259
|
428
|
-39 %
|
-39 %
|
1,392
|
1,369
|
+2 %
|
+3 %
|
|
on outlook
base2
|
489
|
373
|
|
+31 %
|
1,812
|
1,540
|
|
+18 %
|
|
|
|
|
|
|
|
|
|
|
Net
income3
|
67
|
188
|
-64 %
|
-62 %
|
538
|
499
|
+8 %
|
+9 %
|
|
on outlook
base2
|
266
|
154
|
|
+73 %
|
912
|
644
|
|
+42 %
|
|
|
|
|
|
|
|
|
|
|
Basic EPS
(EUR)
|
0.23
|
0.64
|
-64 %
|
-62 %
|
1.83
|
1.70
|
+8 %
|
+9 %
|
|
on outlook
base2
|
0.91
|
0.52
|
|
+73 %
|
3.11
|
2.19
|
|
+42 %
|
|
|
|
|
|
|
|
|
|
|
yoy = year-on-year, cc
= at constant currency, EPS = earnings per share
|
Execution against the strategic plan translates into strong
financial performance and further momentum
Fresenius Medical Care, the world's leading provider of
products and services for individuals with renal diseases,
successfully finished year two of a three-year strategic turnaround
and transformation plan.
Operational efficiency: In 2024, the FME25
transformation program accelerated its momentum, delivering
EUR 221 million additional
sustainable savings for the full year 2024, ahead of the upgraded
full year target of around EUR 200
million. Accumulated savings of the entire program reached
EUR 567 million. Related one-time
costs were EUR 180 million in 2024,
adding up to EUR 599 million since
the start of the program in 2021. The program is unfolding a strong
momentum, which allows to raise the target for sustainable annual
savings by EUR 100 million to now
EUR 750 million by the end of the
current year. The Company assumes related one-time costs of
EUR 700 million to EUR 750 million for the total FME25
transformation program.
Portfolio Optimization: Fresenius Medical Care
continues the execution of its portfolio optimization plan to exit
non-core and dilutive assets. During 2024, the exit of clinic
operations in multiple markets were announced and, except for
Brazil, also closed. Those exits
include all Latin American countries, Sub-Saharan Africa, and
Türkiye, as well as the divestments of Cura Day Hospitals Group in
Australia and select assets of
Spectra Laboratories, our U.S. laboratory testing services
business. All assets divested during 2024 include 230 facilities,
8,200 employees and around 33,800 dialysis patients. Divestitures
closed or held for sale in 2024 negatively impacted revenue by
EUR 306 million and resulted in a
negative effect on operating income of EUR
288 million in the full year 2024, treated as special items
to operating income. As announced, the Company used the proceeds
from divestitures to further improve the leverage ratio.
Capital Allocation: During 2024, Fresenius Medical Care
strictly followed its disciplined financial policy. An increase of
10% in Free Cash Flow after investing activities, mainly due to
proceeds from divestitures, was used to further reduce its net
financial debt by 9% to EUR 9.8
billion. The corresponding net leverage ratio (net
debt/EBITDA) decreased to 2.9x at the end of 2024, compared to 3.2x
at the end of 2023. The Company adheres to its dividend policy of
developing dividends in line with the development of net income
excluding special items. Consequently, the planned dividend
proposal for fiscal year 2024 of EUR
1.44 per share corresponds to an increase by 21% compared to
prior year's dividend.
Revenue development driven by robust organic
growth1
In the fourth quarter 2024, Group revenue increased by 2%
to EUR 5,085 million (+2% at constant
currency, +7% organic1). Revenue on outlook
base2 increased by 5% to EUR
5,069 million compared to prior year. Divestitures realized
as part of the portfolio optimization plan affected the revenue
development by -250 basis points.
Care Delivery revenue decreased by 1% to
EUR 3,945 million (-1% at constant
currency, +6% organic1) and increased by 3% on outlook
base2. Divestitures realized as part of the portfolio
optimization plan affected the revenue development by -370 basis
points.
In Care Delivery U.S., revenue increased by 1% (+1% at constant
currency, +7% organic1) and by 8% on outlook
base2. Growth in the U.S. was driven by the value-based
care business and an overall increase in treatment volumes, higher
reimbursement rates and a favorable payor mix shift, partially
offset by the absence, in 2024, of the Tricare Settlement. U.S.
same market treatment growth further improved sequentially.
Adjusted for the exit from less profitable acute care contracts
(-0.1%), underlying U.S. same market treatment growth remained
positive (+0.5%) compared to prior year for the second consecutive
quarter.
In Care Delivery International, revenue decreased by 10% (-10%
at constant currency, +4% organic1) and by 17% on
outlook base2. This development was driven by
divestments realized as part of the portfolio optimization plan
(-1,980 basis points), partially offset by organic
growth1 and an increase in dialysis days. International
same market treatment growth was positive at 1.5%.
Care Enablement revenue grew by 11% to EUR 1,537 million (+11% at constant currency,
+10% organic1) and by 10% on outlook base2,
driven by volume growth in all our geographical regions as well as
positive pricing momentum. Volume-based procurement in China developed in line with expectations and
was supportive of volume growth, yet a headwind to price
development.
Within Inter-segment eliminations, revenue for products
transferred between the operating segments at fair market value
increased by 8% to EUR 397 million
(+8% at constant currency)4.
In the full year 2024, Group revenue decreased by 1% to
EUR 19,336 million (stable at
constant currency, +4% organic1). On outlook
base2, revenue increased by 2%, in line with the full
year outlook. Divestitures realized as part of the portfolio
optimization plan impacted the revenue development by ‑160 basis
points. Care Delivery revenue decreased by 2% to EUR 15,275 million (-2% at constant currency, +4%
organic1). Care Delivery U.S. grew by 1% (+1% at
constant currency, +4% organic1) and Care Delivery
International decreased by 15% (-13% at constant currency, +4%
organic1). Divestitures realized as part of the
portfolio optimization plan affected the revenue development of
Care Delivery by -230 basis points and the revenue development of
Care Delivery International by -1,230 basis points. Adjusted
for the exit from less profitable acute care contracts (-0.2%),
underlying U.S. same market treatment growth turned positive at
0.1%. Care Enablement revenue increased by 4% to EUR 5,557 million (+5% at constant currency, +5%
organic1). Inter-segment eliminations increased by 2% to
EUR 1,496 million (+2% at constant
currency)4.
Strong operating income growth supported by both
segments
In the fourth quarter 2024, Group operating income
decreased by 39% to EUR 259 million
(-39% at constant currency), resulting in a margin2 of
5.1% (Q4 2023: 8.6%). Operating income on outlook base2
increased by 31% to EUR 489 million,
resulting in a margin2 of 9.6% (Q4 2023: 7.7%).
Divestitures realized as part of the portfolio optimization plan
had a neutral effect on operating income2 margin
development in the fourth quarter.
Operating income in Care Delivery decreased by 51% to
EUR 253 million (-51% at constant
currency), resulting in a margin of 6.4% (Q4 2023: 13.0%). Previous
year's quarter included the positive impact of the Tricare
settlement in the net amount of EUR 181
million. Operating income on outlook
base2 increased by 10%, resulting in a
margin2 of 10.7% (Q4 2023: 10.0%). This growth was
mainly driven by a lower negative contribution from the value-based
care business, positive volume and price effects as well as savings
associated with the FME25 program. The positive development was
partly offset by the phasing of a consent agreement on certain
pharmaceuticals and higher personnel expenses.
Operating income in Care Enablement significantly
increased to EUR 71 million (Q4
2023:
EUR -42 million), resulting in a
margin of 4.6% (Q4 2023: -3.1%). Operating income on outlook
base2 grew by more than sixfold compared to prior year,
resulting in a margin2 of 7.8% (Q4 2023: 1.3%).
This strong increase was driven by positive volume and price
effects as well as savings from the FME25 program, compensating
inflationary cost increases as well as negative price impacts from
volume-based procurement in China.
Operating income for Corporate amounted to EUR -57 million (Q4 2023: EUR -44 million). The development includes the
negative valuation effects of virtual power purchase agreements
(EUR ‑7 million). Operating income on outlook
base2 amounted to EUR ‑42 million (Q4 2023:
EUR -26 million).
In the full year 2024, Group operating income
increased by 2% to EUR 1,392 million
(+3% at constant currency), resulting in a margin of 7.2% (FY 2023:
7.0%). Operating income on outlook base2 increased by
18% to EUR 1,812 million, reaching
the upper end of the tightened full year outlook and resulting in a
margin of 9.3% (FY 2023: 8.1%). Divestitures realized during the
full year were neutral on operating income margin development.
In Care Delivery, operating income declined by 22% to EUR 1,190 million (-21% at constant currency),
resulting in a margin of 7.8% (FY 2023: 9.7%). Operating income
margin on outlook base2 improved to 10.3% (FY 2023:
9.7%). In Care Enablement, operating income significantly increased
to EUR 267 million (FY 2023: EUR ‑67
million), resulting in a margin of 4.8% (Q4 2023: -1.2%). Operating
income margin on outlook base2 increased to 6.1% (FY
2023: 2.3%). Operating income for Corporate amounted to
EUR -48 million (FY 2023: ‑67
million).
Net income3 in the fourth
quarter 2024 decreased by 64% to EUR 67 million (-62%
at constant currency). Previous year's quarter included the
positive impact of the Tricare settlement in the net amount of
EUR 110 million. Net income on
outlook base2 strongly increased by 73%.
In the full year 2024, net income3 increased
by 8% to EUR 538 million (+9% at
constant currency). Net income on outlook base2
increased by 42%.
Basic earnings per share (EPS) decreased by 64% to
EUR 0.23 in the fourth quarter
2024 (-62% at constant currency). EPS on outlook
base2 increased by 73% to EUR
0.91.
In the full year 2024, EPS increased by 8% to
EUR 1.83 (+9% at constant currency).
EPS on outlook base2 increased by 42% to
EUR 3.11.
Lower net financial debt and improved net leverage ratio
driven by robust cash flow development
Fresenius Medical Care improved operating cash flow by
16% to EUR 832 million (Q4 2023:
EUR 719 million) in the fourth
quarter 2024, resulting in a margin of 16.4% (Q4 2023: 14.4%).
Operating cash flow increased mainly due to a favorable working
capital development, which was partially offset by the absence, in
2024, of the Tricare settlement.
In the full year 2024, operating cashflow decreased by 9% to
EUR 2,386 million (FY 2023:
EUR 2,629 million), resulting in a
margin of 12.3% (FY 2023: 13.5%). The decline was mainly driven by
a negative impact from the phasing of dividend payments received
from equity method investments and the absence, in 2024, of the
Tricare settlement.
Free cash flow5 increased by 25%
to EUR 599 million in the fourth
quarter (Q4 2023:
EUR 480 million), resulting in a
margin of 11.8% (Q4 2023: 9.6%). In the full year 2024, free cash
flow decreased by 13% to EUR 1,701
million (FY 2023: EUR 1,960
million), resulting in a margin of 8.8% (FY 2023:
10.1%).
Total net debt and lease liabilities were
further reduced to EUR 9,803 million
(Q4 2023: EUR 10,760 million). The
net leverage ratio (net debt/EBITDA) improved from 3.2x in Q4 2023
to 2.9x in Q4 2024.
Patients, clinics and employees
As of December 31, 2024, Fresenius
Medical Care treated 299,352 patients in 3,675 dialysis
clinics worldwide and had 111,513 employees
(headcount) globally, compared to 119,845 employees as of
December 31, 2023.
Outlook 2025
In 2025, Fresenius Medical Care expects revenue growth to be
positive to a low-single digit percent rate compared to prior
year.
The Company expects operating income to grow by a high-teens to
high-twenties percent rate compared to prior year.
The expected growth rates for 2025 are at constant currency,
excluding special items2 in operating income. The 2024
basis for the revenue outlook is EUR 19,336
million and for the operating income outlook is EUR 1,797 million.
Press conference
Fresenius Medical Care will host a virtual press conference to
discuss the results of the fourth quarter and the full year 2024
today, February 25, 2024, at
10:00 a.m. CET / 4:00 a.m. EST. The press conference will be
webcasted in the "Media" section (Link: Events | Fresenius Medical
Care). A replay will be available shortly after the conference.
Investor conference call
Fresenius Medical Care will host a conference call for analysts
and investors to discuss the results of the fourth quarter and the
full year 2024 today, February 25,
2025, at 2:00 p.m. CET /
8:00 a.m. ET. Details are available
on the Fresenius Medical Care website in the "Investors" section. A
replay and a transcript will be available shortly after the
call.
Please refer to our statement of earnings included at the end of
this news and to the attachments as separate PDF files for a
complete overview of the results of the fourth quarter and full
year 2024. Our 20-F disclosure provides more details.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products
and services for individuals with renal diseases of which around
4.2 million patients worldwide regularly undergo dialysis
treatment. Through its network of 3,675 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for approx. 299,000
patients around the globe. Fresenius Medical Care is also the
leading provider of dialysis products such as dialysis machines or
dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock
Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website
at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject
to various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements
due to various factors, including, but not limited to, changes in
business, economic and competitive conditions, legal changes,
regulatory approvals, results of clinical studies, foreign exchange
rate fluctuations, uncertainties in litigation or investigative
proceedings, and the availability of financing. These and other
risks and uncertainties are detailed in Fresenius Medical Care's
reports filed with the U.S. Securities and Exchange Commission.
Fresenius Medical Care does not undertake any responsibility to
update the forward-looking statements in this release.
|
_____________________________
|
|
1 At
constant currency, adjusted for certain reconciling items including
revenues from acquisitions, closed or sold operations and
differences in dialysis days
|
|
2 Revenue
and operating income outlook, as referred to in the 2024 outlook,
are both at constant currency, excluding special items as well as
the business impact from closed divestitures in 2023 and the
settlement agreement with the U.S. government (Tricare) in 2023.
For FY 2023 and 2024, special items include costs related to the
FME25 program, the Humacyte remeasurements, the legal form
conversion costs and effects from legacy portfolio optimization.
For further details please see the reconciliation attached to the
Press Release.
|
|
3 Net income
attributable to shareholders of Fresenius Medical Care
AG
|
|
4 The
company transfers products between segments at fair market value.
The associated internal revenues and expenses and all other
consolidation of transactions are included within "Inter-segment
eliminations".
|
|
5 Net cash
provided by / used in operating activities, after capital
expenditures, before acquisitions/divestitures, investments, and
dividends
|
|
Statement of
earnings
|
|
|
Three months ended
December 31,
|
|
in € million, except
share data
|
2024
|
2023
|
Change
|
Change
at cc
|
|
|
|
|
|
|
Revenue
|
5,085
|
4,988
|
1.9 %
|
1.6 %
|
|
Revenue (outlook
base)1
|
5,069
|
4,834
|
|
4.9 %
|
|
|
|
|
|
|
Costs of
revenue
|
3,814
|
3,638
|
4.8 %
|
4.5 %
|
|
Selling, general and
administrative expense
|
840
|
845
|
-0.7 %
|
-0.8 %
|
|
Research and
development expense
|
50
|
66
|
-24.1 %
|
-24.3 %
|
|
Income from equity
method investees
|
(32)
|
(23)
|
37.6 %
|
37.6 %
|
|
Other operating
income
|
(228)
|
(257)
|
-11.5 %
|
-11.3 %
|
|
Other operating
expense
|
382
|
291
|
30.9 %
|
29.3 %
|
|
Operating
income
|
259
|
428
|
-39.5 %
|
-38.7 %
|
|
Operating income
(outlook base)1
|
489
|
373
|
|
31.0 %
|
|
|
|
|
|
|
Interest expense,
net
|
80
|
85
|
-5.7 %
|
-6.4 %
|
|
Income before
taxes
|
179
|
343
|
-47.8 %
|
-46.6 %
|
|
Income tax
expense
|
61
|
86
|
-29.4 %
|
-28.6 %
|
|
Net
income
|
118
|
257
|
-54.0 %
|
-52.7 %
|
|
Net income attributable
to noncontrolling interests
|
51
|
69
|
-25.4 %
|
-25.9 %
|
|
Net
income2
|
67
|
188
|
-64.4 %
|
-62.5 %
|
|
Net income2
(outlook base)1
|
266
|
154
|
|
72.9 %
|
|
|
|
|
|
|
Weighted average number
of shares
|
293,413,449
|
293,413,449
|
|
|
|
|
|
|
|
|
Basic earnings per
share
|
€0.23
|
€0.64
|
-64.4 %
|
-62.5 %
|
|
Basic earnings per
share (outlook base)1
|
€0.91
|
€0.52
|
|
72.9 %
|
|
|
|
|
|
|
In percent of
revenue
|
|
|
|
|
|
Operating income
margin
|
5.1 %
|
8.6 %
|
|
|
|
Operating income margin
(outlook base)1
|
9.6 %
|
7.7 %
|
|
|
|
|
|
|
|
|
1 Outlook
base as referred to the 2024 outlook, presented at constant
currency, excluding special items, business
impacts from closed divestitures in 2023 and the Tricare
settlement. For a reconciliation, please refer to the table at
the
end of the press release
|
|
2
Attributable to shareholders of FME AG
|
|
|
|
|
|
Statement of
earnings
|
|
|
|
Twelve months ended
December 31,
|
|
|
in € million, except
share data
|
2024
|
2023
|
Change
|
Change
at cc
|
|
|
|
|
|
|
|
|
Revenue
|
19,336
|
19,454
|
-0.6 %
|
0.0 %
|
|
|
Revenue (outlook
base)1
|
19,454
|
19,049
|
|
2.1 %
|
|
|
|
|
|
|
|
|
Costs of
revenue
|
14,579
|
14,529
|
0.3 %
|
1.0 %
|
|
|
Selling, general and
administrative expense
|
3,143
|
3,196
|
-1.7 %
|
-1.2 %
|
|
|
Research and
development expense
|
183
|
232
|
-20.9 %
|
-20.9 %
|
|
|
Income from equity
method investees
|
(135)
|
(122)
|
10.7 %
|
10.7 %
|
|
|
Other operating
income
|
(760)
|
(515)
|
47.5 %
|
47.8 %
|
|
|
Other operating
expense
|
934
|
765
|
22.1 %
|
22.5 %
|
|
|
Operating
income
|
1,392
|
1,369
|
1.7 %
|
2.6 %
|
|
|
Operating income
(outlook base)1
|
1,812
|
1,540
|
|
17.6 %
|
|
|
|
|
|
|
|
|
Interest expense,
net
|
335
|
336
|
-0.3 %
|
-0.2 %
|
|
|
Income before
taxes
|
1,057
|
1,033
|
2.3 %
|
3.5 %
|
|
|
Income tax
expense
|
316
|
301
|
5.2 %
|
6.3 %
|
|
|
Net
income
|
741
|
732
|
1.1 %
|
2.3 %
|
|
|
Net income attributable
to noncontrolling interests
|
203
|
233
|
-13.1 %
|
-12.8 %
|
|
|
Net
income2
|
538
|
499
|
7.8 %
|
9.4 %
|
|
|
Net income2
(outlook base)1
|
912
|
644
|
|
41.6 %
|
|
|
|
|
|
|
|
|
Weighted average number
of shares
|
293,413,449
|
293,413,449
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per
share
|
€1.83
|
€1.70
|
7.8 %
|
9.4 %
|
|
|
Basic earnings per
share (outlook base)1
|
€3.11
|
€2.19
|
|
41.6 %
|
|
|
|
|
|
|
|
|
In percent of
revenue
|
|
|
|
|
|
|
Operating income
margin
|
7.2 %
|
7.0 %
|
|
|
|
|
Operating income margin
(outlook base)1
|
9.3 %
|
8.1 %
|
|
|
|
|
|
|
|
|
|
|
1 Outlook
base as referred to the 2024 outlook, presented at constant
currency, excluding special items, business
impacts from closed divestitures in 2023 and the Tricare
settlement. For a reconciliation, please refer to the table at
the end of the press release
|
|
|
2
Attributable to shareholders ofFME AG
|
|
|
|
|
|
|
Reconciliation of
non-IFRS financial measures to the most directly
comparable IFRS Accounting
Standards financial measures for comparability with the
Company´s outlook (outlook base)
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
December 31,
|
Twelve months ended
December 31,
|
|
in € million
|
2024
|
2023
|
2024
|
2023
|
|
|
|
|
|
|
Operating
performance (outlook base)
|
|
|
|
|
|
These items are
excluded to ensure comparability of the figures presented
with the Company's financial targets which have been defined
excluding
special items and at constant currency
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
5,085
|
4,988
|
19,336
|
19,454
|
|
Divestitures1
|
—
|
37
|
—
|
(214)
|
|
Tricare
settlement
|
—
|
(191)
|
—
|
(191)
|
|
Revenue excl. 2023
divestitures and Tricare settlement
|
5,085
|
4,834
|
19,336
|
19,049
|
|
Currency translation
effects
|
(16)
|
—
|
118
|
—
|
|
Revenue (outlook
base)
|
5,069
|
4,834
|
19,454
|
19,049
|
|
|
|
|
|
|
Operating
income
|
259
|
428
|
1,392
|
1,369
|
|
FME25
Program
|
73
|
52
|
180
|
153
|
|
Legal Form Conversion
Costs
|
4
|
17
|
9
|
30
|
|
Legacy Portfolio
Optimization2
|
146
|
57
|
288
|
204
|
|
Humacyte
Remeasurements
|
7
|
1
|
(72)
|
(15)
|
|
Sum of special
items:
|
230
|
127
|
405
|
372
|
|
Divestitures1
|
—
|
(1)
|
—
|
(20)
|
|
Tricare
settlement
|
—
|
(181)
|
—
|
(181)
|
|
Sum of special items,
2023 divestitures and Tricare settlement
|
230
|
(55)
|
405
|
171
|
|
Operating income excl.
special items, 2023 divestitures and Tricare
settlement
|
489
|
373
|
1,797
|
1,540
|
|
Currency translation
effects
|
0
|
—
|
15
|
—
|
|
Operating income
(outlook base)
|
489
|
373
|
1,812
|
1,540
|
|
|
|
|
|
|
Net
income3
|
67
|
188
|
538
|
499
|
|
FME25
Program
|
53
|
37
|
130
|
109
|
|
Legal Form Conversion
Costs
|
3
|
12
|
7
|
21
|
|
Legacy Portfolio
Optimization2
|
138
|
21
|
282
|
138
|
|
Humacyte
Remeasurements
|
5
|
1
|
(54)
|
(11)
|
|
Sum of special
items:
|
199
|
71
|
365
|
257
|
|
Divestitures1
|
—
|
5
|
—
|
(2)
|
|
Tricare
settlement
|
—
|
(110)
|
—
|
(110)
|
|
Sum of special items,
2023 divestitures and Tricare settlement
|
199
|
(34)
|
365
|
145
|
|
Net income3
excl. special items, 2023 divestitures and Tricare
settlement
|
266
|
154
|
903
|
644
|
|
Currency translation
effects
|
0
|
—
|
9
|
—
|
|
Net income3
(outlook base)
|
266
|
154
|
912
|
644
|
|
|
|
|
|
|
1 Business
impacts from closed divestitures in 2023
|
|
2 2024:
mainly comprise gains and losses from divestitures,
impairment losses resulting from the measurement of assets held for
sale
or from write-downs of related non-current assets; 2023: mainly
comprise the derecognition of capitalized development costs and
the
impairment of intangible assets (licenses and distribution rights)
as well as termination costs (including certain contractual
obligation
expenses) related to a dialysis cycler development program which
was discontinued in the first quarter of 2023 and other impacts
related
to agreed-upon divestitures in 2023
|
|
3
Attributable to shareholders of FME AG
|
Media contact
Christine
Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@freseniusmedicalcare.com
www.freseniusmedicalcare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-delivers-18-earnings-growth-in-2024-and-continues-the-acceleration-momentum-into-2025-302384002.html
SOURCE Fresenius Medical Care Holdings, Inc.
